Ceretype Neuromedicine, a Cambridge, MA-based company which specializes in the practical application and integration of functional MRI (fMRI), closed its second round of seed financing.
The $2M funding target was oversubscribed. The round was led by Cedar Street Group. Other participants included Leafy Tunnel, The One Mind Accelerator and private investors.
The company intends to use the funds to help advance its fMRI platform.
Led by CEO Emily Stern, Ceretype has pioneered the practical application & integration of fMRI in neuropsychiatric drug development and beyond. Its platform makes targeted biomarkers accessible, delivering actionable evidence to improve drug discovery and patient care. Through its technical approach and its ability to sub-type and classify the human brain on a neurobiological level, Ceretype offers biologically-based therapeutic insights.
FinSMEs
05/01/2024